Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Publications (10 of 78) Show all publications
Bytyci, I., Bytyqi, S., Lewek, J., Surma, S., Bajraktari, G., Henein, M., . . . Banach, M. (2025). Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis. European Heart Journal Open, 5(1), Article ID oeaf001.
Open this publication in new window or tab >>Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis
Show others...
2025 (English)In: European Heart Journal Open, E-ISSN 2752-4191, Vol. 5, no 1, article id oeaf001Article in journal (Refereed) Published
Abstract [en]

Aims; Heterozygous familial hypercholesterolaemia (HeFH) is one of the most frequent monogenic disorders in the world, leading to premature atherosclerotic cardiovascular diseases. The aim of this meta-analysis was to evaluate the efficacy and safety of lipid-lowering therapy (LLT) and achievement of low density lipoprotein cholesterol (LDL-C) goal in children with HeFH.

Methods and results: The main endpoint was efficacy of goal achievement for LDL-C and other lipid parameters: total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein B, and lipoprotein(a), and the LLT safety [adverse events (AEs), including endocrine function, and growth indices]. The secondary endpoint was an effect of LLT on attainment of LDL-C goal treatment (<3.5 mmol/L/130 mg/dL). A total of 41 studies with 4667 paediatric patients at mean age 12.08 ± 2.4 years were included. Seventeen reported the efficacy and safety of LLT therapy compared to control, while the remaining assessed LLT through pre- and post-treatment. At median follow-up of 18.8 months, the group on LLT had significantly higher mean reductions of TC, LDL-C, TG, and increased HDL-C compared to control [−1.75 mmol/L (−67.7 mg/dL), −1.84 mmol/L (−71.2 mg/dL), −0.11 mmol/L (−9.74 mg/dL), 0.08 mmol/L (3.1 mg/dL), respectively, P < 0.001 for all]. In the subgroup analysis according to different types of LLT, we observed a significantly higher mean reduction of LDL-C by statin combined with ezetimibe treatment, followed by statins in monotherapy, PCSK9 inhibitors, and monotherapy with ezetimibe [−2.48 mmol/L (−95.9 mg/dL), −2.16 mmol/L (−83.5 mg/dL), −2.03 mmol/L (−78.5 mg/dL), and −1.50 mmol/L (−58 mg/dL), respectively, test for overall effect: P < 0.001]. The pooled LDL-C was reduced by 33.44% [−2.14 mmol/L (−82.8 mg/dL), P < 0.001] and failed to reach the goal treatment (<3.5 mmol/L) by 12.6% (95% CI, 12.4-12.9%). A total of 38.7% of children achieved the LDL-C goal, 23.9% fell short by up to 10%, 10.7% experienced moderate failure (were over the LDL-C target between >10% and 20%), and 26.7% failed by more than 20% to reach the LDL-C target. When comparing different regions, only Sweden and Greece achieved the LDL-C goal < 3.5 mmol/L in the follow-up. Netherlands, Norway, Poland, USA, UK, France, Spain, Belgium, and Austria required 2.2%, 3.4%, 3.5%, 8.9%, 10.2%, 11.2%, 11.2%, 15%, and 19.4% additional reduction in LDL-C respectively to achieve the LDL-C goal of < 3.5 mmol/L. All other countries required over 20% additional reduction in LDL-C to achieve the LDL-C goal. For other investigated countries, over 20% mean LDL-C reduction was required. All parameters related to endocrine function and demographic indices were unaffected by LLT therapy (P > 0.05). The AEs were not reported significantly higher when compared to the control, and the prevalence of therapy discontinuation was only 0.8%.

Conclusion: Despite the efficacy of LLT in children with HeFH and the low occurrence of discontinuation-related adverse events, achieving LDL-C treatment goals was relatively rare, with large differences between the investigated countries. These results underscore the importance of considering early combination therapy of statins and ezetimibe, and PCSK9 inhibitors (if available) to attain LDL-C goals effectively.

Place, publisher, year, edition, pages
Oxford University Press, 2025
Keywords
Children, Efficacity, Heterozygous familial hypercholesterolaemia, LDL-C target, Safety
National Category
Cardiology and Cardiovascular Disease Endocrinology and Diabetes
Identifiers
urn:nbn:se:umu:diva-236495 (URN)10.1093/ehjopen/oeaf001 (DOI)2-s2.0-85219653217 (Scopus ID)
Available from: 2025-03-18 Created: 2025-03-18 Last updated: 2025-03-18Bibliographically approved
Ismaili, J., Ibrahimi, P., Berisha-Muharremi, V., Karahoda, R., Berbatovci-Ukimeraj, M., Istrefi, N., . . . Bajraktari, G. (2025). Predictors of subclinical atherosclerosis in asymptomatic healthy non-diabetic postmenopausal women. Clinical Physiology and Functional Imaging, 45(1), Article ID e12920.
Open this publication in new window or tab >>Predictors of subclinical atherosclerosis in asymptomatic healthy non-diabetic postmenopausal women
Show others...
2025 (English)In: Clinical Physiology and Functional Imaging, ISSN 1475-0961, E-ISSN 1475-097X, Vol. 45, no 1, article id e12920Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND AIM: Cardiovascular disease progresses after menopause. Conventional risk factors, particularly diabetes, for atherosclerosis are well-established predictors of phenotypic arterial disease. The aim of this study is to assess the predictors of subclinical atherosclerosis in asymptomatic non-diabetic postmenopausal women.

METHODS: This prospective study included 117 consecutive postmenopausal women (mean age 59 ± 7 years) referred from the outpatient Rheumatology Clinic of the University Clinical Centre of Kosovo, recruited between September 2021 and December 2022. Clinical, biochemical, carotid ultrasound and coronary CT angiography data were analysed. Subclinical atherosclerosis was diagnosed when plaque and/or carotid intima-media thickness >1.00 mm were present.

RESULTS: Women who had subclinical atherosclerosis had higher erythrocyte sedimentation (p = 0.022), higher total cholesterol (p = 0.013), higher CAC score (p = 0.017), and higher prevalence of CAC > 100 HU and CAC > 400 HU (p = 0.017 and p = 0.034, respectively) compared to those without subclinical atherosclerosis. Women who had mild coronary calcification (CAC score ≥10 HU) were older (p = 0.005), in longer menopause (p = 0.005), had thicker CIMT (p = 0.008) with higher prevalence (p = 0.03) compared to those with CAC score <10 HU. Women with moderate coronary calcification (CAC score ≥100 HU) had higher triglycerides, worse CIMT (p = 0.005) with higher prevalence (p = 0.039) compared to those with CAC score <100 HU. In multivariate analysis [odds ratio 95% confidence interval], age [1.101 (1.032-1.174), p = 0.037] and cholesterol [2.020 (1.225-3.331), p = 0.006] independently predicted the presence of subclinical atherosclerosis.

CONCLUSIONS: In addition to the impact of age, hypercholesterolaemia is an important predictor of subclinical atherosclerosis in non-diabetic postmenopausal women.

Place, publisher, year, edition, pages
John Wiley & Sons, 2025
Keywords
atherosclerosis, carotid ultrasound, coronary calcification, menopause, women
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-233847 (URN)10.1111/cpf.12920 (DOI)001379600300001 ()39688094 (PubMedID)2-s2.0-85212907157 (Scopus ID)
Available from: 2025-01-09 Created: 2025-01-09 Last updated: 2025-02-10Bibliographically approved
Bajraktari, G. (2025). The Kosovo society of cardiology: the youngest member in the ESC family. European Heart Journal, 46(11), 994-995
Open this publication in new window or tab >>The Kosovo society of cardiology: the youngest member in the ESC family
2025 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 46, no 11, p. 994-995Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Oxford University Press, 2025
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-237403 (URN)10.1093/eurheartj/ehae785 (DOI)001398350200001 ()39820995 (PubMedID)2-s2.0-105001219541 (Scopus ID)
Available from: 2025-04-10 Created: 2025-04-10 Last updated: 2025-04-10Bibliographically approved
Batalli, A., Henein, M. Y., Poniku, A., Ibrahimi, P., Pllana-Pruthi, E., Elezi, S., . . . Bajraktari, G. (2024). Management and clinical outcome of myocardial infarction in Kosovo: a cross-sectional study. Health Science Reports, 7(10), Article ID e70122.
Open this publication in new window or tab >>Management and clinical outcome of myocardial infarction in Kosovo: a cross-sectional study
Show others...
2024 (English)In: Health Science Reports, E-ISSN 2398-8835, Vol. 7, no 10, article id e70122Article in journal (Refereed) Published
Abstract [en]

Background and Aims: Myocardial infarction (MI) is a major cause of mortality worldwide, irrespective of its presentation as non-ST-segment elevation MI (NSTEMI) or ST-segment elevation MI (STEMI). The objective of this study was to assess national results of management and clinical outcome of acute MI patients in Kosovo.

Methods: This cross-sectional descriptive study, conducted at the Clinic of Cardiology of the University Clinical Center of Kosovo, in Prishtina, included all patients hospitalized with acute MI over a period of 7 years (2014-2020). The primary outcome of the study was in-hospital mortality.

Results: Among 7353 admitted patients with acute MI (mean age 63 ± 12 years, 29% female) and according to the final diagnosis, 4436 (59.4%) patients had STEMI, and 2987 (40.6%) NSTEMI. More patients with STEMI received primary percutaneous intervention (PPCI) than those with NSTEMI (50% vs. 41%, p < 0.001). In-hospital mortality was higher in no PPCI patients compared to PPCI both in NSTEMI (10.7% vs. 2.6%, p < 0.001) and STEMI (20.9% vs. 6.8%, p < 0.001). Age ≥65 years [0.399 (0.267–0.597), p ˂ 0.001], hemoglobin level [0.889 (0.815–0.970), p = 0.008], STEMI [0.491 (0.343–0.704), p ˂ 0.001], lack of PPCI [2.636 (1.798–3.866), p ˂ 0.001], cardiogenic shock [0.002 (0.001–0.006), p < 0.001], reduced left ventricular ejection fraction (LV EF) [0.966 (0.951–0.980), p < 0.001], and heart rate at admission [1.009 (1.000–1.017), p = 0.047], independently predicted mortality. In STEMI, cardiogenic shock (p ˂ 0.001), lack of PPCI (p = 0.006), female gender (p = 0.01), and low LV EF (p = 0.04) predicted mortality but age ≥65 years (p = 0.02), female gender (p = 0.02), low LV EF (p = 0.007), and low hemoglobin (p = 0.04) predicted mortality in NSTEMI.

Conclusion: Between 2014 and 2020, half of patients with acute MI were not treated with PPCI, who had high mortality, particularly when presenting with STEMI. Age, cardiogenic shock, anemia, low LV EF, STEMI and no PPCI independently predicted mortality. Cardiogenic shock and lack of PPCI independently predicted mortality, only in STEMI.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
acute myocardial infarction, Kosovo, mortality, primary PCI
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-231302 (URN)10.1002/hsr2.70122 (DOI)001334255500001 ()39421209 (PubMedID)2-s2.0-85206814463 (Scopus ID)
Available from: 2024-11-06 Created: 2024-11-06 Last updated: 2025-02-10Bibliographically approved
Bajraktari, G., Bytyci, I., Abdyli, G., Ibrahimi, P., Bajraktari, A., Karahoda, R., . . . Henein, M. Y. (2024). One-month dual antiplatelet therapy reduces major bleeding compared with longer-term treatment without excess stent thrombosis: a systematic review and meta-analysis of randomized clinical trials. American Journal of Cardiology, 227, 91-97
Open this publication in new window or tab >>One-month dual antiplatelet therapy reduces major bleeding compared with longer-term treatment without excess stent thrombosis: a systematic review and meta-analysis of randomized clinical trials
Show others...
2024 (English)In: American Journal of Cardiology, ISSN 0002-9149, E-ISSN 1879-1913, Vol. 227, p. 91-97Article, review/survey (Refereed) Published
Abstract [en]

Dual antiplatelet therapy (DAPT) remains the gold standard in patients who underwent percutaneous coronary intervention (PCI). This meta-analysis aims to evaluate the clinical safety of 1-month DAPT followed by aspirin or a P2Y12 receptor inhibitor after PCI with drug-eluting stents (DES). We searched PubMed, MEDLINE, Embase, Scopus, Google Scholar, Cochrane Central Registry, and ClinicalTrials.gov databases and identified 5 randomized controlled trials with 29,831 patients who underwent PCI with DES and compared 1-month versus >1-month DAPT. The primary end point was major bleeding, and the co-primary end point was stent thrombosis. The secondary end point included all-cause mortality, cardiovascular death, myocardial infarction, stroke, and major adverse cardiovascular or cerebrovascular events. Compared with >1-month DAPT, the 1-month DAPT was associated with a lower rate of major bleeding (odds ratio [OR] 0.66, 95% confidence interval [CI] 0.45 to 0.97, p = 0.03, I2 = 71%), whereas stent thrombosis had a similar rate in both study groups (OR 1.08, 95% CI 0.81 to 1.44, p = 0.60, I2 = 0.0%). The study groups had similar risks for all-cause mortality (OR 0.89, 95% CI 0.77 to 1.04, p = 0.14, I2 = 0.0%), cardiovascular death (OR 0.84, 95% CI 0.59 to 1.19, p = 0.32, I2 = 0.0%), myocardial infarction (OR 1.04, 95% CI 0.89 to 1.21, p = 0.62, I2 = 0.0%), and stroke (OR 0.82, 95% CI 0.64 to 1.05, p = 0.11, I2 = 6%). The risk of major adverse cardiovascular or cerebrovascular events was lower (OR 0.86, 95% CI 0.76 to 0.97, p = 0.02, I2 = 25%) in the 1-month DAPT compared with >1-month DAPT. In conclusion, in patients who underwent PCI with DES, 1-month DAPT followed by aspirin or a P2Y12 receptor inhibitor reduced major bleeding with no risk of increased thrombotic risk compared with longer-term DAPT.

Place, publisher, year, edition, pages
Elsevier, 2024
Keywords
acute coronary syndrome, dual antiplatelet therapy, percutaneous coronary intervention, stable coronary artery disease
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-228567 (URN)10.1016/j.amjcard.2024.07.010 (DOI)001295097700001 ()39029722 (PubMedID)2-s2.0-85200854598 (Scopus ID)
Available from: 2024-08-20 Created: 2024-08-20 Last updated: 2025-04-24Bibliographically approved
Poniku, A., Batalli, A., Shita, D., Rexhaj, Z., Ferati, A., Leka, R., . . . Bajraktari, G. (2024). Smoking and hypertriglyceridemia predict st-segment elevation myocardial infarction in Kosovo patients with acute myocardial infarction. Clinics and Practice, 14(3), 1149-1158
Open this publication in new window or tab >>Smoking and hypertriglyceridemia predict st-segment elevation myocardial infarction in Kosovo patients with acute myocardial infarction
Show others...
2024 (English)In: Clinics and Practice, ISSN 2039-7275, E-ISSN 2039-7283, Vol. 14, no 3, p. 1149-1158Article in journal (Refereed) Published
Abstract [en]

Background: Myocardial infarction (MI), presented as ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI), is influenced by atherosclerosis risk factors. Aim: The aim of this study was to assess the patterns of presentation of patients with acute MI in Kosovo. Methods: This was a cross-sectional study conducted at the University Clinical Center of Kosovo, which included all patients hospitalized with acute MI over a period of 7 years. Results: Among the 7353 patients admitted with acute MI (age 63 ± 12 years, 29% female), 59.4% had STEMI and 40.6% had NSTEMI. The patients with NSTEMI patients less (48.3% vs. 54%, p < 0.001), but more of them had diabetes (37.8% vs. 33.6%, p < 0.001), hypertension (69.6% vs. 63%, p < 0.001), frequently had a family history of coronary artery disease (CAD) (40% vs. 38%, p = 0.009), and had more females compared to the patients with STEMI (32% vs. 27%, p < 0.001). The patients with NSTEMI underwent less primary percutaneous interventions compared with the patients with STEMI (43.6% vs. 55.2%, p < 0.001). Smoking [1.277 (1.117–1.459), p ˂ 0.001] and high triglycerides [0.791 (0.714–0.878), p = 0.02] were independent predictors of STEMI. Conclusions: In Kosovo, patients with STEMI are more common than those with NSTEMI, and they were mostly males and more likely to have diabetes, hypertension, and a family history of CAD compared to those with NSTEMI. Smoking and high triglycerides proved to be the strongest predictors of acute STEMI in Kosovo, thus highlighting the urgent need for optimum atherosclerosis risk control and education strategies.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
age, arterial hypertension, diabetes, gender, myocardial infarction, risk factors, smoking
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-227758 (URN)10.3390/clinpract14030091 (DOI)001255027600001 ()38921269 (PubMedID)2-s2.0-85197195653 (Scopus ID)
Available from: 2024-07-09 Created: 2024-07-09 Last updated: 2025-02-10Bibliographically approved
Yalta, K., Madias, J. E., Kounis, N. G., Y-Hassan, S., Polovina, M., Altay, S., . . . Seferovic, P. M. (2024). Takotsubo syndrome: an international expert consensus report on practical challenges and specific conditions (part-1: diagnostic and therapeutic challenges). Balkan Medical Journal, 41(6), 421-441
Open this publication in new window or tab >>Takotsubo syndrome: an international expert consensus report on practical challenges and specific conditions (part-1: diagnostic and therapeutic challenges)
Show others...
2024 (English)In: Balkan Medical Journal, ISSN 2146-3123, E-ISSN 2146-3131, Vol. 41, no 6, p. 421-441Article in journal (Refereed) Published
Abstract [en]

In the recent years, there has been a burgeoning interest in Takotsubo syndrome (TTS), which is renowned as a specific form of reversible myocardial dysfunction. Despite the extensive literature available on TTS, clinicians still face several practical challenges associated with the diagnosis and management of this phenomenon. This potentially results in the underdiagnosis and improper management of TTS in clinical practice. The present paper, the first part (part-1) of the consensus report, aims to cover diagnostic and therapeutic challenges associated with TTS along with certain recommendations to combat these challenges.

Place, publisher, year, edition, pages
Galenos Yayinevi, 2024
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-231797 (URN)10.4274/balkanmedj.galenos.2024.2024-9-98 (DOI)001352707000001 ()39417524 (PubMedID)2-s2.0-85208451016 (Scopus ID)
Funder
Swedish Heart Lung FoundationSwedish Society of MedicineRegion Stockholm
Available from: 2024-11-25 Created: 2024-11-25 Last updated: 2025-02-10Bibliographically approved
Yalta, K., Madias, J. E., Kounis, N. G., Y-Hassan, S., Polovina, M., Altay, S., . . . Seferovic, P. M. (2024). Takotsubo syndrome: an international expert consensus report on practical challenges and specific conditions (part-2: specific entities, risk stratification and challenges after recovery). Balkan Medical Journal, 41(6), 442-457
Open this publication in new window or tab >>Takotsubo syndrome: an international expert consensus report on practical challenges and specific conditions (part-2: specific entities, risk stratification and challenges after recovery)
Show others...
2024 (English)In: Balkan Medical Journal, ISSN 2146-3123, E-ISSN 2146-3131, Vol. 41, no 6, p. 442-457Article in journal (Refereed) Published
Abstract [en]

Takotsubo syndrome (TTS) still remains as an enigmatic phenomenon. In particular, long-term challenges (including clinical recurrence and persistent symptoms) and specific entities in the setting of TTS have been the evolving areas of interest. On the other hand, a significant gap still exists regarding the proper risk-stratification of this phenomenon in the short and long terms. The present paper, the second part (part-2) of the consensus report, aims to discuss less well-known aspects of TTS including specific entities, challenges after recovery and risk-stratification.

Place, publisher, year, edition, pages
Galenos Yayinevi, 2024
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-231770 (URN)10.4274/balkanmedj.galenos.2024.2024-9-99 (DOI)001352122200001 ()39417538 (PubMedID)2-s2.0-85208452020 (Scopus ID)
Funder
Swedish Heart Lung FoundationSwedish Society of MedicineRegion Stockholm
Available from: 2024-11-25 Created: 2024-11-25 Last updated: 2025-02-10Bibliographically approved
Bajraktari, G., Elezi, S., Bytyci, I., Ibrahimi, P., Abdyli, G., Pllana-Pruthi, E., . . . Henein, M. Y. (2024). The rationale and design of the KOSovan Acute Coronary Syndrome (KOS-ACS) Registry. Diagnostics, 14(14), Article ID 1486.
Open this publication in new window or tab >>The rationale and design of the KOSovan Acute Coronary Syndrome (KOS-ACS) Registry
Show others...
2024 (English)In: Diagnostics, ISSN 2075-4418, Vol. 14, no 14, article id 1486Article in journal (Refereed) Published
Abstract [en]

The KOSovan Acute Coronary Syndrome (KOS-ACS) Registry is established as a prospective, continuous, nationwide, web-based registry that is operated online. The KOS-ACS registry is designed with the following objectives: (1) to obtain data on the demographic, clinical, and laboratory characteristics of ACS patients treated in Kosovo; (2) to create a national database with information on health care in ACS patients treated in Kosovo; (3) to identify the national features of associations between ACS characteristics and clinical outcomes, including mortality, complications, the length of hospital stay, and the quality of clinical care; and (4) to propose a practical guide for improving the quality and efficiency of ACS treatment in Kosovo. The Kosovo Society of Cardiology and University of Prishtina will be responsible for the development of the KOS-ACS registry and centralized data analysis at the national level. The KOS-ACS Registry will enroll all patients admitted, at any of the registered clinical centers, with the diagnosis of ACS and who will be clinically managed at any of the Kosovo hospitals. Data on patient demographics, clinical characteristics, previous and hospital drug treatment, and reperfusion therapy will be collected. The type of ACS (unstable angina, NSTEMI, or STEMI) will also be clearly defined. The time from first medical contact to balloon inflation (FMC-to-balloon) and door-to-ballon time will be registered. In-hospital death and complications will be registered. Data on the post-hospital primary outcome (MACE: cardiac death, all-cause mortality, hospitalization, stroke, need for coronary revascularization) of patients, at 30 days and 1 year, will be included in the registry.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
acute coronary syndrome, in-hospital mortality, Kosovo, outcomes, registry
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-228192 (URN)10.3390/diagnostics14141486 (DOI)001276593100001 ()39061623 (PubMedID)2-s2.0-85200057373 (Scopus ID)
Available from: 2024-08-07 Created: 2024-08-07 Last updated: 2025-02-10Bibliographically approved
Dini, F. L., Baldini, U., Bytyci, I., Pugliese, N. R., Bajraktari, G. & Henein, M. Y. (2023). Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome. International Journal of Cardiology, 374, 129-134
Open this publication in new window or tab >>Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome
Show others...
2023 (English)In: International Journal of Cardiology, ISSN 0167-5273, E-ISSN 1874-1754, Vol. 374, p. 129-134Article in journal (Refereed) Published
Abstract [en]

Background: The long COVID-19 syndrome has been recently described and some reports have suggested that acute pericarditis represents important manifestation of long COVID-19 syndrome. The aim of this study was to identify the prevalence and clinical characteristics of patients with long COVID-19, presenting with acute pericarditis.

Methods: We retrospectively included 180 patients (median age 47 years, 62% female) previously diagnosed with COVID-19, exhibiting persistence or new-onset symptoms ≥12 weeks from a negative naso-pharyngeal SARS CoV2 swamp test. The original diagnosis of COVID-19 infection was determined by a positive swab. All patients had undergone a thorough physical examination. Patients with suspected heart involvement were referred to a complete cardiovascular evaluation. Echocardiography was performed based on clinical need and diagnosis of acute pericarditis was achieved according to current guidelines.

Results: Among the study population, shortness of breath/fatigue was reported in 52%, chest pain/discomfort in 34% and heart palpitations/arrhythmias in 37%. Diagnosis of acute pericarditis was made in 39 patients (22%). Mild-to-moderate pericardial effusion was reported in 12, while thickened and bright pericardial layers with small effusions (< 5 mm) with or without comet tails arising from the pericardium (pericardial B-lines) in 27. Heart palpitations/arrhythmias (OR:3.748, p = 0.0030), and autoimmune disease and allergic disorders (OR:4.147, p = 0.0073) were independently related to the diagnosis of acute pericarditis, with a borderline contribution of less likelihood of hospitalization during COVID-19 (OR: 0.100, p = 0.0512).

Conclusion: Our findings suggest a high prevalence of acute pericarditis in patients with long COVID-19 syndrome. Autoimmune and allergic disorders, and palpitations/arrhythmias were frequently associated with pericardial disease.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
Acute pericarditis, COVID-19, SARS-CoV2
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:umu:diva-202257 (URN)10.1016/j.ijcard.2022.12.019 (DOI)000963714400001 ()36513284 (PubMedID)2-s2.0-85144783643 (Scopus ID)
Available from: 2023-01-05 Created: 2023-01-05 Last updated: 2025-02-10Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0003-0410-968x

Search in DiVA

Show all publications